Search

With patent commercialization, the value of the patent increases even more. In order for patents to be commercialized, first of all, the inventions that are the subject of the patent must be effectively introduced to potential customers. It is important to determine the stage of promotion of patents to potential customers and the market share of patented products. Considering the market aspect in patent commercialization, in this study, it has been tried to evaluate the patents in terms of Business Readiness Level BRL (Business Readiness Level) scale (Raghu, 2017) by using the patent maturity test of university patents. For this purpose, a literature study on Business Readiness Level BRL (Business Readiness Level), Technology Readiness Level TRL (Technology Readiness Level) and patent maturity was conducted. A survey was conducted with the inventors of the patents owned by Fırat University and the patent applications made. In line with the data obtained from the surveys, evaluations were made regarding the TRL and BRL levels of the patents. As a result of this study, it has been determined that the technological readiness level (TRL) of the patents of Fırat University is at a good level. Despite the high level recorded in TRL, it was determined that the job readiness level (BRL) was not high. Suggestions have been made to achieve an increase in the Business Readiness Level (BRL). [ABSTRACT FROM AUTHOR]

In this study, drug protection methods in the context of globalization and rational drug use were examined within the scope of patent protection and data protection. Inventions are protected by patents and utility models. Turkey is a signatory to several international agreements for the protection of industrial property rights including patents, utility models, trademarks, geographical signs and designs has been carried out effectively. In accordance with the Trade-Related Intellectual Property Rights (TRIPs) Agreement annexed to the World Trade Organization Agreement which includes provisions on the need to protect intellectual and industrial property rights in all member states in a standard manner, Turkey was obliged to accept patent applications related drugs since 1 January 1995.In accordancewith the 6 March 1995 and 1/95 of the Turkey-European Union AssociationCouncil Decision and the 23 June 1995 and 566 numbered Decreeof both procedure and product patent protection in Turkey has been under provisions will begin from 1 January 1999. The data protection obligation that originates from TRIPs, which is a protection method different from patent protection, entered our legislation in 1995.In this context, the confidentiality of the information provided for licensing is secured. Turkey, on 1 January 2005 the reference drug producing innovator firms which will provide relief in the market for a 6-year data exclusivity application was enacted. In order to avoid possible negative effects on the cost of treatment of patent and data protection which is the application appears to be a necessary for Turkey patented drugs parallel imports and production under compulsory licensing should be encouraged as well as rational drug use which supports the use of generic drugs. Drug policies that promote generic drug production need to be implemented and the pharmaceutical industry should be supported in this context. [ABSTRACT FROM AUTHOR]